A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
*Sign up for news summaries and alerts from 340B Report